New Real-World Study Highlights Adherence Challenges in Glaucoma Therapy with CONNECTDROP®

Publication Date: October 5, 2025

A new real-world clinical study sponsored by Laboratoires Thea is shedding light on the critical challenge of adherence to intraocular pressure (IOP)–lowering therapy among glaucoma patients. The study utilizes CONNECTDROP®, a medical device designed to enhance patient compliance and improve therapeutic outcomes.

Healthcare professionals and regulatory teams involved in glaucoma therapy and medical device evaluation should take note of the trial’s implications for adherence-related strategies. The study is currently recruiting participants.

What changed?

This real-world study marks an important advancement in understanding the role of medical devices like CONNECTDROP® in addressing non-adherence to glaucoma therapy. Non-adherence to IOP-lowering treatments is a well-recognized issue that can lead to progression of glaucoma and subsequent vision loss. The study aims to generate evidence on whether CONNECTDROP® can effectively promote better adherence among patients.

The study’s recruiting status, combined with its real-world design, makes it uniquely positioned to provide clinically relevant insights.

About the study

CONNECTDROP® is a medical device developed to support glaucoma patients in maintaining their treatment regimens. Laboratoires Thea, the sponsor of the trial, is known for its focus on innovative solutions that address unmet needs in ophthalmology. The current study examines adherence rates among patients using the therapy in a real-world setting over an extended period.

Objectives

The primary objective is to assess adherence to prescribed IOP-lowering regimens when utilizing the CONNECTDROP® device. Secondary outcomes include analyzing whether improved adherence translates to better IOP control and overall disease management.

Design and Recruitment

This is an observational study currently recruiting participants. Inclusion and exclusion criteria have been defined to enroll glaucoma patients already under or prescribed a therapeutic regimen. Details about trial registration and protocol adherence can be found on ClinicalTrials.gov.

Potential implications

This study has the potential to inform regulatory, clinical, and patient education strategies. For regulatory teams, the data could support broader evaluations of adherence-enhancing medical devices. For clinicians, the findings will be instrumental in guiding practice to mitigate non-adherence in glaucoma management.

The study also reflects broader trends in personalized medicine and real-world evidence generation. By focusing on practical outcomes, such as adherence in non-idealized conditions, the trial underscores the importance of patient and product interaction in real life.

Frequently Asked Questions

1. What is the main focus of the study?
The study examines adherence to IOP-lowering therapy in patients using the CONNECTDROP® device.

2. Who sponsors this study?
The study is sponsored by Laboratoires Thea.

3. Who might benefit from this research?
Regulatory and clinical teams, as well as healthcare providers involved in glaucoma management.

4. Where can I find more details?
Complete trial details are available at ClinicalTrials.gov under the identifier NCT07206628.

Conclusion

Understanding how medical devices can improve patient adherence is critical in managing chronic conditions such as glaucoma. This study represents an important step forward in exploring the role of CONNECTDROP® in real-world settings. Healthcare teams involved in glaucoma treatment should monitor the trial’s outcomes closely for insights into improving patient care.

Disclaimer

This content is for informational purposes and does not constitute legal or regulatory advice. Stakeholders should consult relevant regulatory authorities or experts for detailed guidance.

Announcement source

For full information about the announcement, see the link below.

https://clinicaltrials.gov/study/NCT07206628?term=medical+device